Tonix Pharmaceuticals Holding (TNXP) EV to EBITDA (2014 - 2026)

Tonix Pharmaceuticals Holding has reported EV to EBITDA for 13 years, with the latest figure at 0.89 in Q2 2026.

• On a quarterly basis, EV to EBITDA rose 82.58% year-over-year to 0.89 in Q2 2026; TTM through Jun 2026 was 0.23, a 86.96% increase from a year earlier, with the FY2025 full-year figure at 0.59, up 7.75% from the prior year.
• EV to EBITDA was 0.89 for Q2 2026 at Tonix Pharmaceuticals Holding, down from 0.24 in the prior quarter.
• The five-year high for EV to EBITDA was 4.72 in Q2 2022, with the low at 5.13 in Q2 2025.
• Average EV to EBITDA over 5 years is 0.71, with a median of 0.51 recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: EV to EBITDA surged 1298.58% in 2024, then slumped 30719.5% in 2025.
• Over 5 years, EV to EBITDA stood at 3.26 in 2022, then sank by 78.6% to 0.7 in 2023, then surged by 381.48% to 3.35 in 2024, then plunged by 53.87% to 1.55 in 2025, then sank by 157.81% to 0.89 in 2026.
• The last three EV to EBITDA figures came in at 0.89 (Q2 2026), 0.24 (Q1 2026), and 1.55 (Q4 2025), per Business Quant data.